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Abstract
Background: Gout is a metabolic syndrome characterized by: 1.) hyperuricemia and deposition of urate (uric
acid) crystals causing attacks of acute inflammatory arthritis; 2.) tophi around the joints and possible joint
destruction; 3.) renal glomerular, tubular and interstitial disease and; 4.) uric acid urolithiasis. According to
the U.S. Census Bureau, whose numbers were obtained from a year 2005 population estimate study, gout
affected an estimated 6.1 million adults aged 20 years old and older. Many challenges are faced with the
treatment of gout, however, the mainstay of hypouricemic treatment has been the conventional use of
allopurinol. In February of 2009, the FDA approved a new medication, Uloric (febuxostat), which claimed to
be more effective than Zylporim (allopurinol) for chronic sufferers of gout who have long been dissatisfied
with previously available options in the treatment of hyperuricemia.
Hypothesis: Patients who did not receive the expected level of benefit from treatment with allopurinol to
adequately reduce urate levels in the body, now have a greater likelihood of success with the aid of a new
pharmaceutical tool, febuxostat.
Study Design: A review of literature on Uloric (febuxostat), as well as Zyloprim (allopurinol), was performed
via an exhaustive search of available studies within the time frame ranging from 2004 through the present,
completed on the adult population, utilizing Medline-Ovid, Web of Science, WorldCat.org, PubMed, and the
Chochrane Central Register of Randomised Controlled Trials.
Methods: Including a search of the keywords listed below, multiple reference lists of articles obtained were
also checked for any additional sources that might have been overlooked in the original search. Studies that
were included were phase I through phase III clinical trials that examined solely febuxostat, as well as
febuxostat compared to allopurinol. Studies that were excluded were those that did not primarily focus on the
treatment of gout utilizing the two aforementioned medications—e.g. probenecid, indomethacin, and
colchicine. As a result, a systematic review of the obtained literature regarding the comparison of febuxostat-
treatment versus allopurinol-treatment on hyperuricemia and gout was completed.
Results: A combination of phase I and phase II trials, eight in total, were analyzed for background testing
completed on the new drug. Two critical Phase III Randomly-Controlled Trial articles with two additional
long term studies were obtained that displayed febuxostat to have an advantage over allopurinol in the
treatment of hyperuricemia and gout.
Conclusion: Febuxostat proved to be more effective in reducing the serum uric acid concentration in subjects
with hyperuricemia and gout. Febuxostat showed promising hypouricemic effects among those individuals
tested with renal-impairment, distancing itself from allopurinol. However, due to the recentness of FDA
approval and unfamiliarity in the clinic setting, further observations of febuxostat’s long term efficacy and
safety need to be done on a greater number of gout and hyperuricemic patients.
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Abstract   
 
Background:  Gout is a metabolic syndrome characterized by: 1.) hyperuricemia and 
deposition of urate (uric acid) crystals causing attacks of acute inflammatory arthritis; 2.) 
tophi around the joints and possible joint destruction; 3.) renal glomerular, tubular and 
interstitial disease and; 4.) uric acid urolithiasis.  According to the U.S. Census Bureau, 
whose numbers were obtained from a year 2005 population estimate study, gout affected 
an estimated 6.1 million adults aged 20 years old and older.  Many challenges are faced 
with the treatment of gout, however, the mainstay of hypouricemic treatment has been the 
conventional use of allopurinol.  In February of 2009, the FDA approved a new 
medication, Uloric (febuxostat), which claimed to be more effective than Zylporim 
(allopurinol) for chronic sufferers of gout who have long been dissatisfied with 
previously available options in the treatment of hyperuricemia. 
Hypothesis:  Patients who did not receive the expected level of benefit from treatment 
with allopurinol to adequately reduce urate levels in the body, now have a greater 
likelihood of success with the aid of a new pharmaceutical tool, febuxostat.     
Study Design:  A review of literature on Uloric (febuxostat), as well as Zyloprim 
(allopurinol), was performed via an exhaustive search of available studies within the time 
frame ranging from 2004 through the present, completed on the adult population, 
utilizing Medline-Ovid, Web of Science, WorldCat.org, PubMed, and the Chochrane 
Central Register of Randomised Controlled Trials. 
Methods:  Including a search of the keywords listed below, multiple reference lists of 
articles obtained were also checked for any additional sources that might have been 
overlooked in the original search.  Studies that were included were phase I through phase 
III clinical trials that examined solely febuxostat, as well as febuxostat compared to 
allopurinol.  Studies that were excluded were those that did not primarily focus on the 
treatment of gout utilizing the two aforementioned medications—e.g. probenecid, 
indomethacin, and colchicine.   As a result, a systematic review of the obtained literature 
regarding the comparison of febuxostat-treatment versus allopurinol-treatment on 
hyperuricemia and gout was completed.   
Results:  A combination of phase I and phase II trials, eight in total, were analyzed for 
background testing completed on the new drug.  Two critical Phase III Randomly-
Controlled Trial articles with two additional long term studies were obtained that 
displayed febuxostat to have an advantage over allopurinol in the treatment of 
hyperuricemia and gout.       
Conclusion:  Febuxostat proved to be more effective in reducing the serum uric acid 
concentration in subjects with hyperuricemia and gout.  Febuxostat showed promising 
hypouricemic effects among those individuals tested with renal-impairment, distancing 
itself from allopurinol.  However, due to the recentness of FDA approval and 
unfamiliarity in the clinic setting, further observations of febuxostat’s long term efficacy 
and safety need to be done on a greater number of gout and hyperuricemic patients 
Keywords: Gout, Uloric, Febuxostat, TMX-67, Treatment, Alllpurinol, Zyloprim, 
Xanthine Oxidase Inhibitors, Hyperuricemia, Uric Acid.   
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THE EFFECTIVENESS OF NEWLY FDA APPROVED ULORIC (FEBUXOSTAT) 
VERSUS THE CONVENTIONALLY USED ZYLOPRIM (ALLOPURINOL) IN 
TREATMENT OF HYPERURICEMIA AND CHRONIC GOUT IN THE ADULT 
POPULATION 
 
Introduction 
 
In February of 2009, the FDA approved a new medication, Uloric (febuxostat), 
which claimed to be more effective than Zylporim (allopurinol) for chronic sufferers of 
gout who have long been dissatisfied with previously available options in the treatment of 
hyperuricemia.  A comparison between febuxostat and allopurinol proved necessary to 
aid in the treatment of multiple individuals that questioned the efficacy and necessity to 
treat gout conventionally with the medication allopurinol.  Chronic sufferers of painfully 
intense gout attacks, these individuals were in search of an alternative to failed multiple 
attempts solely treated with allopurinol.  Since clinical profiles were quite similar in 
presentation, the patients lacked any other comorbidities with comparable medical 
histories, treatment with the newly FDA-approved medication, Uloric (febuxostat), was 
initiated.   
Prior to the start of drug administration, however, lab values needed to be drawn 
to assess the serum uric acid level, liver function, renal function, and overall assessment 
of health (lipid panel, complete blood count, comprehensive metabolic profile, and 
urinalysis).  Focusing on the uric acid (urate) levels found in the individuals, all displayed 
a level of >8.0mg/dL, diagnostically implicating hyperuricemia (Normal range= 3.0 
mg/dL and 7.0 mg/dL)1.  All other lab values were within normal limits, so the drug 
prescriptions were written and obtained.  Future follow up appointments were scheduled 
for close monitoring.  As a result, within 2 weeks, the subjects’ uric acid levels had been 
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reduced nearly 40% to <6.0 mg/dL with no acute gout attacks experienced within the 
short treatment time prior to follow up.    
As a Physician Assistant student, inquiring the proper methods to treat certain 
ailments and illnesses was thought to be a task with which the information at goal would 
be found with conclusive, concrete certainty.  However, the realistic roots of Clinical 
Medicine and Evidence Based Medicine would reveal the aforementioned ideology to be 
naïve in nature.  The destination, or endpoint, is not necessarily the most difficult 
attribute of Medicine, as ultimately, the goal is to heal, it is the process or path through 
which we reach that goal which proves to be the most complex.  With that being stated, 
“Is Uloric (febuxostat) a clinically wiser choice over Zyloprim (allopurinol) for treatment 
of hyperuricemia which is found in gout?”   
 
Background 
 Gout is a metabolic syndrome characterized by: 1.) hyperuricemia and deposition 
of urate (uric acid) crystals causing attacks of acute inflammatory arthritis; 2.) tophi 
around the joints and possible joint destruction; 3.) renal glomerular, tubular and 
interstitial disease and; 4.) uric acid urolithiasis.  However, all of the above do not have to 
be concomitantly present to clinically establish an individual with gout.  The disease most 
commonly affects monoarticularly, the first toe (podagra), foot, ankle, knee, fingers, wrist 
and elbow, but can affect any joint.2  
 There exist four classifications, or stages, of gout that are distinguished, with the 
first noted as Asymptomatic Hyperuricemia.  Elevated levels of urate are present within 
the body, but the individual does not display symptoms clinically.  It is common for a 
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patient to have an elevated uric acid level for a length of time, possibly even for years, 
before an acute attack may occur.  While in this stage, it is not necessary to administer 
treatment, including any uric acid-lowering agents. 
 Stage 2, an acute gout attack or flare, comprises of the build up and small deposits 
of monosodium urate crystals in and around specific joint spaces.  The invasion and 
buildup within the joint spaces triggers a cascade of physiologic events that leads to the 
inflammation of the affected joint(s).  Characteristically, the patient may suffer pain, 
redness, swelling, and warmth, which may last for lengths of time ranging from days to 
weeks.  Within the acute gout flare, it is primarily the arthritis that is treated, with the 
underlying hyperuricemia weeks later, as an aggressive and sudden reduction of serum 
uric acid often precipitates further episodes of gouty arthritis.3  Therefore, NSAIDs are 
the treatment of choice for acute gout flares.  Traditional use of the medication 
Indomethacin has been the NSAID of choice, but this should not preclude the use of 
alternative drugs from the same class.  Other drugs including Colchicine and 
corticosteroids (useful in patients with contraindications to the use of NSAIDs) have also 
been utilized by clinicians in the treatment of acute flares.   
 Intercritical Gout occurs in a patient who has had prior gout flares, which have 
successfully subsided and who has no current expression of gout symptoms.  A patient 
may report normal joint function, though hyperuricemia continues to occur with an 
increasingly greater possibility for damage in tissues due to continued deposition of urate 
crystals.   As an indication of the progression and severity of gout, the intercritical 
periods between flares will shorten as the disease escalates.  It is at this phase, which may 
include frequent acute arthritis flares, tophaceous deposits, and/or renal damage, that 
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serum uric acid reduction intervention is indicated.  For introductory purposes, two 
classes of agents may be used to reduce uric acid: uricosuric drugs-e.g. probenecid or 
sulfinpyrazone; and allopurinol, a xanthine oxidase inhibitor.  
 The final stage of progression, Chronic Gout, is typified by a resulting destructive 
and disabling inflammatory process causing ongoing pain and aching of the joint(s).  
Chronic tophaceous arthritis is a product of the continuous deposition of urate crystals 
around and within the joint space.  In multiple cases, deformities and destruction of the 
bone and joints involved have occurred, not surprisingly, causing a reduction in quality of 
life due to the damage and pain. 
Clinical manifestations of acute and chronic arthritis, tophi at the joints, and renal 
disease, are direct representations of the length and intensity of hyperuricemia in 
individuals that suffer from gout.  Uric acid, therefore, is the fulcrum on which clinicians 
base gout-treatment and potential resolution due to its direct association with the risk of 
gout.4,5  Consequently, the logical, most advantageous treatment methodology, entails 
maintenance control of serum uric acid levels below the supersaturation concentration 
threshold within the human body.  By doing so, urate crystal deposition into the certain 
anatomical locations is fundamentally avoided.  Monosodium urate crystals tend to 
supersaturate and precipitate into body fluids and the human body’s blood serum, if the 
concentration is >6.8mg/dL.  In effect, the target of urate-lowering therapy is to reduce 
patients’ serum urate concentrations ideally to <6.0mg/dL in order to cut the number of 
gout attacks, or better yet, to prevent any possibility of a recurrent gout attack.6   
 The amount of urate in the body depends on the balance between dietary intake, 
the synthesis, and rate of excretion within each individual.  Gout patients fall into two 
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groups, which sometimes overlap.  In the first group, which accounts for roughly 10% of 
cases, hyperuricemia results from urate overproduction.  Found in the second group, the 
other 90% of cases, hyperuricemia results from underexcretion of urate from the body.7  
 Figure 1 displays a brief, overall physiological schematic of urate balance within 
the human body.  As a catabolic product of purine metabolism, uric acid can reach 
hyperuricemic levels that can potentiate the risk of causing gout symptoms.  Uric acid is 
formed when hypoxanthine, the precursor of xanthine in the metabolic process of purine 
to urate, is enzymatically degraded by the liver enzyme, xanthine oxidase.  Xanthine 
oxidase also catalyzes the final step of the metabolic pathway, with the conversion of 
xanthine to urate (see Figure 2).  Most excretion of excess urate is then handled by the 
kidneys, while a third is done by the gastrointestinal tract.  It is through these simplified 
mechanisms where uricosuric drugs, allopurinol, and febuxostat, take action chemically.   
 Uricosuric drugs such as probenecid or sulfinpyrazone block the tubular 
reabsorption of the filtered urate thereby reducing the excess urate within the body fluids.  
Obviously, due to their mechanism and effect on the kidneys, the uricosuric agents are 
counterindicated for patients with renal insufficiency or who have renal impairment.  
Allopurinol is a xanthine oxidase inhibitor which acts on the catabolic pathway from 
hypoxanthine to urate.  Febuxostat acts in very much the same manner as allopurinol, 
however, unlike the latter, febuxostat is not purine-like in structure, nor does it affect any 
other enzymes in the purine and pyrimidine pathways.8, 9 
Purpose of Study 
 According to the U.S. Census Bureau, whose numbers were obtained from a year 
2005 population estimate study, gout affected an estimated 6.1 million adults aged 20 
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years old and older.10  Gout is also especially common in Pacific Islanders, e.g. Filipinos 
and Samoans, who are a large representation of the population of Hawaii.  Additionally 
and often overlooked, hospitalized patients frequently suffer acute gout attacks due to 
unavoidable changes in their dietary regimen, fluid intake, and medications.  These 
changes have the potential then, to lead either to rapid reductions or to increases in the 
serum urate level.   
Studies rooted in obtaining evidence to display the upslope of gout prevalence and 
disease burden prove that the need for care alternatives and techniques is evident.11 
Therapeutically, the interventions and medications currently available fall short of 
success.  On that note, allopurinol can be utilized as a first-line drug for serum urate-
lowering therapy, and can be administered in doses up to 800mg daily.  However, 
clinicians are commonly reluctant to prescribe dosages of more than 300mg per day due 
to the medical risk of possible renal damage associated in higher doses.12 Consequently, 
by restricting the dosage so, the drug often fails to adequately treat the underlying 
hyperuricemia found in gout. 
Quality of life and adherence to urate-lowering therapies of the affected patients 
are directly hindered in parallel to the shortcomings in quality of care administered.13, 14  
With the advent of the newly FDA approved febuxostat, a potential alternative is at the 
least, now available for utilization.  Therefore, it is hypothesized that patients who did not 
receive the expected level of benefit from treatment with allopurinol to adequately reduce 
urate levels in the body, now have a greater likelihood of success with the aid of a new 
pharmaceutical tool, febuxostat.     
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Methods and Materials 
 A review of literature on Uloric (febuxostat), as well as Zyloprim (allopurinol), 
was performed via an exhaustive search of available studies within the time frame 
ranging from the year of 2004 through the present, completed on the adult population, 
utilizing Medline-Ovid, Web of Science, WorldCat.org, PubMed, and the Chochrane 
Central Register of Randomised Controlled Trials.  Key search terms included in the 
search were: “Gout”, “Uloric”, “Febuxostat”, “TMX-67”, “Treatment”, “Allopurinol”, 
“Zyloprim”, “Xanthine Oxidase Inhibitors”, “Hyperuricemia” and “Uric Acid”.  Multiple 
reference lists of articles obtained were also checked for any additional sources that 
might have been overlooked in the original search.  Studies that were included were 
phase I through phase III clinical trials that examined solely febuxostat, as well as 
febuxostat compared to allopurinol.  Studies that were excluded were those that did not 
primarily focus on the treatment of gout utilizing the two aforementioned medications—
e.g. probenecid, indomethacin, and colchicine.   As a result, a systematic review of the 
obtained literature regarding the comparison of febuxostat-treatment versus allopurinol-
treatment on hyperuricemia and gout was completed.    
 
Results 
In regards to obtaining scientific clinically-tested data dealing with febuxostat 
(Uloric), two critical Phase III Randomly-Controlled Trial articles (The Febuxostat 
versus Allopurinol Controlled Trial, or FACT; and The Allopurinol-and Placebo-
Controlled, Efficacy Study of Febuxostat, or APEX study) were obtained from database 
searches which specifically compared the recently formulated urate-lowering drug with 
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allopurinol.  Also, a series of relatively long-term studies (FOCUS and EXCEL studies) 
have been carried out to assess the attributes of febuxostat, as the FACT and APEX 
studies were stopped after 52 weeks and 28 weeks respectively.  Prior to the comparison 
trials listed above, Phase I and II clinical trials were as well conducted, however more 
emphasis will be placed onto the controlled trials that directly contrasted febuxostat and 
allopurinol in the treatment of hyperuricemia and gout.   
A succinct summary of Phase I and Phase II clinical tests and publications can be 
seen on Table I within the Tables section of this review.  The table highlights multiple 
aspects of which febuxostat was reviewed.  Khosravan, R. put forth a bulk of the findings 
including the effects of Age and Gender on febuxostat on healthy individuals (n=96), the 
effects of food and/or antacid use on febuxostat on healthy individuals (n=92), the effect 
of combining NSAID (indomethacin and/or naproxen) use with febuxostat on healthy 
individuals (Study 1: n=26 and Study 2: n=25), the effect on hepatic impairment on 
febuxostat (n=26), and a dose escalation study (n=12) that contributed to further other 
dose-studies of febuxostat performed by Mayer and Becker.  The outcomes of the 
Khosravan works were as follows:  No dose adjustments of febuxostat based on gender or 
age alone were necessary15; febuxostat can be administered regardless of food or antacid 
intake16; febuxostat may be administered with indomethacin or naproxen with no dose 
adjustments for febuxostat, indomethacin, or naproxen necessary17; febuxostat appears to 
be generally safe and well tolerated in mildly and moderately hepatic groups —no dose 
adjustments were necessary in subjects with mild to moderate hepatic impairment18; and 
lastly, the trials derived a linear pharmacokinetic and dose-response relationship for 
febuxostat dosages within 10-120mg range with a note that febuxostat was found to be 
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extensively metabolized and renal function did not seem to play an important role in 
elimination from the body.19, 15, 16 
Mayer, M. provided further insight with a Phase I, parallel-group, open-label, 
multiple-dose exploration (n=31) that studied the safety, pharmacokinetics, and 
pharmacodynamics of febuxostat in subjects with varying degrees of renal impairment.  
Febuxostat 80mg was administered once-daily for 7 days, and although a plasma 
exposure to the drug and its metabolites was higher in subjects with increasing degrees of 
renal impairment, the percentages of reduction in serum uric acid levels were 
comparable, regardless of renal function.  Therefore, it was concluded that a once-daily 
80mg dose of febuxostat appeared to be safe and well tolerated in different renal function 
groups, requiring no dose adjustments necessary based on differences in renal function in 
individuals.20   
Additional to the dose-escalation study performed by Khosravan, Becker M.A. 
performed a Phase I, multiple-dose, placebo-controlled, dose-escalation study (published 
in 2004), as well as a Phase II randomized, multicenter, double-blinded, placebo-
controlled, dose-response clinical trial (published in 2005).  The former consisted of 154 
healthy subjects, female and male (19-54 years old), tested to determine the safety, 
tolerability, pharmacokinetics, and pharmacodynamics of febuxostat over a range of oral 
doses.  It was found that febuxostat effectively decreased serum uric acid concentrations 
in a dose-linear manner, with once-daily dosing of up to 120mg, and that doses in excess 
of 120mg daily did not appear to provide significant additional hypouricemic effects.  
Also important, Becker noted that since febuxostat did not appear to cause significant 
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reduction in total purine synthesis, he could deduce that the sole mechanism of action of 
febuxostat was indicated to be a xanthine oxidase inhibitor.21  
Within Becker’s Phase II clinical trial, 153 individuals were separated into groups 
to assess the safety and efficacy of once-daily oral febuxostat in doses of 40mg, 80mg, 
120mg, versus placebo for twenty-eight days.  The degree of serum uric acid reduction 
was significantly greater in all febuxostat treatment groups compared to placebo by day 
seven, and those values were maintained over the 28-day study period.  In regards to 
adverse events, febuxostat and placebo groups were found to be equal in incidence, with 
few serious adverse events occurring.  Renal insufficiency was not assessed in this study, 
and future studies were indicated (addressed by studies completed by Mayer in 2005 and 
Khosravan in 2006 discussed above).  Data suggested therapeutic dosages of febuxostat 
were likely to fall in the range of 80mg – 120mg per day, and it provided confirmation 
that febuxostat’s mechanism of action was xanthine oxidase inhibition.22  
Concentrating now on the Febuxostat versus Allopurinol Controlled Trial 
(FACT), the attention shifts to contrasting the efficacy and safety of febuxostat versus 
allopurinol in adult subjects with hyperuricemia and gout.  The FACT study was a Phase 
III, randomized, double-blinded, 52-week, multicenter trial that compared adult 
individuals with gout and a serum uric acid level of at least 8.0 mg/dL.  A stated total of 
762 subjects were recruited and randomized by a computer-generated randomization 
schedule into groups that would either receive febuxostat 80mg once-daily, febuxostat 
120mg once-daily, or allopurinol 300mg daily for a time period of 52 weeks.  For 
subjects that were already receiving urate-lowering therapy, a washout period of two 
weeks occurred before randomization.  During the two week washout, as well as the first 
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eight weeks of double-blinded treatment, naproxen (250mg twice a day) or colchicine 
(0.6mg daily) was administered for gout flare prophylaxis.   
Physical examination checkpoints were performed at two weeks and four weeks, 
and then monthly thereafter.  Data from each patient/subject consisted of vital signs, 
serum urate concentration, renal function, compliance with study drugs, laboratory tests, 
concomitant medication use, gout flares, and adverse events.   The primary efficacy 
endpoint was serum urate concentration of less than 6.0mg/dL at each of the last three 
monthly measurements.  Secondary efficacy endpoints included the proportion of 
subjects with serum urate levels of less than 6.0mg/dL at each visit and the percentage 
reduction from baseline in the serum urate concentration at each visit.  Additionally just 
as important, the clinical endpoints, were the percentage reduction from baseline in 
tophus area, the change in number of tophi at each visit, and the proportion of subjects 
requiring treatment for acute gout flares from weeks 9-52.   
As seen in Tables 2 and 3, the primary endpoint of reaching a serum urate 
concentration of <6.0mg/dL at all of the final three measurements at monthly intervals 
was reached in 53%, 62%, and 21% in the febuxostat 80mg, febuxostat 120mg, and 
allopurinol 300mg subject groups, respectively.  P-values of <0.001 were derived for the 
comparison of each febuxostat group with the allopurinol group establishing it as a 
statistically significant finding.  The overall outcome in regards to the incidence of acute 
gout flares displayed a gradual decrease similar across all test groups.  By weeks 49-52 
(final visit interval), the flare incidences were noted to be 08%, 06%, and 11% in the 
febuxostat 80mg, febuxostat 120mg, and allopurinol 300mg groups, respectively.  
Another clinical outcome, the median reduction in tophus area, displayed the values of 
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83% in patients who received febuxostat 80mg, and 66% reduction in patients of the 
febuxostat 120mg group.  In comparison, the allopurinol 300mg test group only had a 
median tophus area reduction of 50% (p-value >0.05, again, proving to be of statistical 
significance).  Lastly, a higher number of subjects (n=98) from the febuxostat 120mg 
group discontinued intervention versus both the febuxostat 80mg (n=88) and allopurinol 
300mg (n=66).  Despite the most common treatment-related adverse events being 
abnormal liver-function tests (febuxostat 80mg = 4%, febuxostat 120mg = 5%, and 
allopurinol 300mg = 4%), diarrhea, headaches, and joint-related symptoms, the authors 
concluded that the febuxostat arms proved to be more successful and effective than the 
allopurinol control group at reducing the serum uric acid levels in individuals with gout.23   
The Allopurinol-and Placebo-Controlled, Efficacy Study of Febuxostat, or APEX 
study, aimed to compare the safety and efficacy of orally administered febuxostat with 
placebo and allopurinol in subjects with hyperuricemia and gout.  Also, the study 
attempted to solidify, confirm, and expand upon the aforementioned FACT trial by 
assessing the effects of treatment in subjects with impaired renal function (serum 
creatinin level >1.5 - ≤2.0mg/dL).  Very much like the FACT study, the APEX study was 
a phase III, randomized, double-blinded, allopurinol-and-placebo-controlled, parallel-
group trial which was conducted at 167 sites in the US and involved 1,072 subjects for 
28-weeks.  Inclusion criteria called for participants with gout, hyperuricemia (≥8.0mg/dL 
sUA), and normal (serum creatinine level ≤1.5mg/dL) or impaired (serum creatinine level 
>1.5 to ≤2.0mg/dL) renal function at day -2.   
After a 2-week washout period for patients with previous urate-lowering therapy, 
subjects were randomized into a 2:2:1:2:1 ratio of once-daily febuxostat 80mg, febuxostat 
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120mg, febuxostat 240mg, allopurinol (300mg or 100mg, dependent on renal function), 
or placebo.  Similar to the FACT study, either colchicine 0.6 mg once daily or naproxen 
250mg twice daily per oral was provided during the washout period, and was continued 
for the first 8 weeks of the study as a prophylaxis for gout flares.  Physical examination 
checkpoints were established every 4 weeks for serum urate levels, laboratory 
assessments, gout flares, adverse events, concomitant medications, and to examine the 
number and size of palpable tophi. 
The primary endpoint of reaching a serum uric acid level of <6.0mg/dL in the 
final 3 visits was reached by subjects with proportions of 36%, 52%, 66%, 10%,and 0% 
in the febuxostat 80mg, 120mg, 240mg, allopurinol 300mg, and placebo groups 
respectively.  A p-value of <0.001 was obtained for febuxostat achieving a greater 
proportion of subjects <6.0mg/dL versus allopurinol or placebo.  For the subjects with 
moderate renal impairment, 44%, 46%, 60%, and 0% achieved a serum uric acid level of 
<6.0 in the febuxostat 80mg, 120mg, 240mg, and allopurinol 100mg groups respectively.   
At the checkpoint of 28 weeks, the proportions of 76%, 87%, 94% 41%, and 1% 
of the febuxostat 80mg, 120mg, 240mg, allopurinol 300mg, and placebo groups achieved 
a serum uric acid level of <6.0mg/dL.  In this case, a p value <0.05 was calculated for the 
comparison of the febuxostat groups versus allopurinol.  The overall reduction of serum 
uric acid showed a 45% decrease for febuxostat 80mg, 52% decrease for febuxostat 
120mg, 66% decrease in febuxostat 240mg, 34% decrease for allopurinol 300mg, and a 
3% decrease in the placebo group. 
 In regards to the incidence of gout flares, there proved to be no significant 
statistical differences between the treatment groups.  This result also held for the number 
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of tophi and median tophus size between all tested groups.  Proven to have a greater 
impact, however, as with the FACT study, the list of adverse events was focused on the 
outcome of abnormal liver function results  
 Adverse events, listed by frequency, included, but were not limited to, upper 
respiratory tract infections, musculoskeletal and connective tissue symptoms, diarrhea, 
joint-related signs and symptoms, headaches, and abnormal findings on liver function 
tests.  Amongst the febuxostat 80mg group 17/51 (6%), the febuxostat 120mg group 
10/51 (4%), the febuxostat 240mg group 06/51 (4%), the allopurinol 300mg group 15/51 
(6%), and placebo group 03/51 (2%) were noted with abnormal liver-function results.  In 
fact, 12 withdrew from the study due to abnormal liver function values (see table for 
number of subjects).  As a final note, 78 subjects across the treatment groups lead to the 
discontinuation of therapy due to adverse events.  These results determined that 
febuxostat demonstrated a greater efficacy compared to allopurinol and placebo in the 
reduction and the maintenance of the serum uric acid level below the suggested 
therapeutic value of 6.0mg/dL.24  
 A long term study termed the FOCUS study followed subjects for 5-years, and 
has measured results similar to endpoints obtained in the FACT and APEX studies.  The 
number of subjects who had a serum uric acid level <6.0mg/dL throughout the long-term 
study was 54/58 subjects, or 93% across all febuxostat dosages (40mg, 80mg, 120mg 
daily).  Dealing with resolution of tophus since baseline of the study, 18 of 26 subjects 
experienced complete resolution.  No deaths had taken place, and after one year of stable 
dosing, all subjects have had less than one gout flare per year (similar to findings of the 
EXCEL study noted in Table 2).  The data led the authors to conclude that long-term 
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treatment with febuxostat resulted in long-lasting maintenance of serum uric acid levels 
below 6.0mg/dL, and nearly complete abolition of gout flares and tophi for a majority of 
subjects within the study.25  
Discussion / Analysis 
 The primary goal of this review was to identify evidence from current available 
medical literature to weigh the benefits and costs of using a newly FDA-approved drug, 
Uloric (febuxostat), versus a mainstay, conventional drug, Zyloprim (allopurinol) for the 
treatment of hyperuricemia and gout.  With the research and development of a new drug, 
many challenges are faced by study facilitators to ensure a scientific, unbiased protocol 
and implementation.  Ideally, one could assume that economic influences and endeavors 
should not influence the procedure, the methods, nor the outcome of the research.  
However, realistically, there is always an inkling of skepticism around a study which has 
been fueled financially by the pharmaceutical company producing the drug, as seen with 
the studies performed on febuxostat.   
Since problems with such studies are being highlighted, the potential lack of 
objectivity is not the only issue.  Both the FACT and the APEX studies claim to be 
double-blinded, but fail to specify the methods of blinding of the medical personnel.  It is 
unclear from what was presented in the evidence whether the investigators and medical 
personnel who administered the interventions were blinded to the treatment similar to the 
subjects.  Again, this creates some hesitation to accept the studies due to lack of clarity 
within methods. 
Within the direct comparison of febuxostat with allopurinol, it is noteworthy that 
the recommended dosage of allopurinol as stated in the medical reference, Epocrates, is 
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100mg initially, with a titrated dosage increase of 100mg to the maximum dosage of 
600mg/day.2  The trials did not test subjects with the maximum dosage due to the 
restriction necessary for renal-impaired patients, as well as to the presumable fear of 
idiopathic kidney damage.  Febuxostat was maximized at its 240mg dosage while the 
highest dose of allopurinol was 300mg amongst subjects without any renal impairment.  
This distorts the result because allopurinol was not tested at its maximized hypouricemic 
potential.  
As displayed in Table 3, the serum uric acid levels were significantly reduced at a 
greater proportion in the febuxostat groups over the allopurinol groups of the FACT and 
APEX studies.  Regardless of the fact that a considerable number of the subjects did not 
meet the primary outcome, claims were still made that febuxostat was superior to 
allopurinol.  More importantly, as seen in the APEX study, when allopurinol’s efficacy 
was rendered completely unsuccessful amongst the subjects with renal impairment, 
febuxostat remained effective without causing any renal effects.   
Allopurinol is a xanthine oxidase inhibitor which acts on the catabolic pathway 
from hypoxanthine to urate.  Febuxostat acts very much in the same manner of 
Allopurinol, however, unlike the latter, Febuxostat is not purine-like in structure nor does 
it affect any other enzymes in the purine and pyrimidine pathways.  In essence, 
febuxostat is a more selective xanthine oxidase inhibitor, and the difference could give 
the ability to treat with renal-impaired patients (febuxostat treatment) versus a possibility 
of unsuccessful treatment causing idiopathic harm (allopurinol treatment).   
The secondary endpoint, the measurement of gout flares and tophi resolution are 
of greater clinical importance.  Patients will present to clinic more commonly with acute 
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gout flare pain and the production of tophi due to hyperuricemia rather than 
asymptomatic hyperuricemia.  Randomized controlled trial evidence showed that, even 
though more febuxostat recipients achieved the serum uric acid endpoint of <6.0 mg/dL, 
this did not equate to an advantage over allopurinol in the clinically evident outcomes of 
acute gout flares and gout tophi reduction.  In the FACT study, acute gout flares were 
reduced to as low as 8 % and 6% in febuxostat groups versus 11% in the allopurinol 
300mg group signifying no clear-cut divergence between the treatments.  Moreover, the 
same trend was found within the subjects for the outcome of gout tophi reduction.  
Similarly, the APEX study also showed no statistically significant differences across 
treatment groups for both the secondary outcomes of acute gout flares and tophi 
reduction.   
In terms of cost, febuxostat 40mg and 80mg is currently distributed for 
approximately $160.00 per month of medication, while allopurinol 300mg (one tablet 
daily) has been currently seen selling for $22.99 for 100 tablets.26 Besides economic 
feasibility, the adverse effects of drug administration are non economic costs.  Both the 
APEX and FACT studies claimed the adverse effects and events were similar across 
treatment groups including notably concern-causing abnormal liver function results.  
Further studies that can concentrate on, or isolate the immediate and long-term effects of 
febuxostat on liver function need to be accomplished to further ensure safety in the 
administration of the drug.  At this point, the makers of febuxostat recommend laboratory 
assessment of liver function at 2 and 4 months following initiation, and periodically 
thereafter.9 
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Conclusion / Recommendations 
Based on the literature review completed, febuxostat proved to be more effective 
in reducing the serum uric acid concentration in subjects with hyperuricemia and gout.  
However, despite febuxostat’s success in contrast with allopurinol, the resolution of the 
clinical symptoms of acute gout flares and tophi showed that febuxostat had no 
significant advantage over its challenger.  A crucial difference between the two drugs is 
that the dosage of allopurinol will have to be adjusted when treating renal-impaired 
individual.  Febuxostat showed promising hypouricemic effects among those individuals 
tested with renal-impairment, distancing itself from allopurinol.  Due to the recentness of 
FDA approval and unfamiliarity in the clinic setting, further observations of febuxostat’s 
long term efficacy and safety need to be done on a greater number of gout and 
hyperuricemic patients.    
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Figures & Tables 
 
Figure 1- The development of gout in terms of sources and excretion.   
 
 
Figure 2 – Simplified pathway of uric acid metabolism with mechanisms of discussed 
gout medications. Uricosuric drugs block the tubular reabsorption of filtered urate in the 
kidneys.  Febuxostat and allopurinol inhibit the enzyme xanthine oxidase. 
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Author Published Study Type Sample Size Treatments Studied Outcomes Final Comments 
 
Khosravan, 
R. 
2008 Phase I  
Parallel-group 
Multiple-dose 
Open-label 
n=96 
 
Healthy female 
and male 
 
18-40yo or ≥65 
yo enrolled 
 
• Oral Febuxostat 80mg (4 
x 20mg tabs daily for 7 
consecutive days 
following an overnight 
fast ≥ 8 hrs 
 
• Effect of Age and 
Gender on Febuxostat 
• The pharmacokinetics, 
pharmacodynamics, and 
safety of Febuxostat do not 
appear to be substanstially 
affected by age or gender 
following multiple dosing 
for 7 days 
• No dose 
adjustment based 
on gender or age 
alone is necessary 
 
• Small sample size  
Khosravan, 
R.  
2007 Phase I  
Randomized 
Single Center 
Crossover 
study 
n=92 
 
 
Healthy female 
and male 
 
18-55yo with 
normal Creat. 
Clearance and 
BMI <30kgm^-
2 
• Single Febuxostat 40mg 
(n=24) 
Vs. 
Multiple Febuxostat 80mg 
(n=24) 
Vs. 
Single Febuxostat 120mg 
(fasting and nonfasting 
conditions) (n=20) 
Vs. 
Single Febuxostat 80mg 
(alone or with antacid) 
(n=24) 
 
• Effect of Food or 
Antacid on Febuxostat 
• Food—caused reduction in 
plasma concentratiom, rate 
and extent of absorption 
 
• Author claims decrease not 
associated with clinically 
significant change is 
pharmacodynamic effect. 
 
• Antacid—caused a 
decrease in the absorption 
rate, but no effect on the 
extent of absorption 
 
• Febuxostat can be 
administered 
regardless of food 
or antacid intake 
 
• Small sample size 
Khosravan, 
R. 
2006 Phase I  
Randomized 
Single-Center 
Open-Label 
Multiple-dose 
3-period 
Crossover 
studies 
Study 1: n=26 
 
Study 2: n=25 
 
Healthy female 
and male  
 
18-55yo  
• Study 1: 5 days 
Febuxostat 80mg daily 
Vs. 
Feb 80mg daily + Indo 50mg 
BID  
Vs 
Indomethacin 50mg BID 
 
• Study 2: 7 days long 
Febuxostat 80mg daily  
• Febuxostat had no effect on 
plasma pharmacokinetics 
of both indomethacin and 
naproxen. 
 
• Indomethacin had no effect 
on plasma 
pharmacokinetics of 
febuxostat 
 
• Febuxostat may 
be administered 
with 
indomethacin or 
naproxen with no 
dose adjustments 
for febuxostat, 
indomethacin, or 
naproxen 
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Vs. 
Feb 80mg daily + Nap 
500mg BID 
Vs.  
Naproxen 500mg BID 
 
• Effect of Febuxostat on 
pharmacokinetics of 
NSAIDS (indomethacin 
and naproxen) and vice 
versa  
• Naproxen caused increase 
in exposure to febuxostat, 
however author claims not 
clinically significant 
• Small sample size 
Khosravan, 
R.  
2006 Phase I 
Parallel-group 
Open-label, 
Mutliple-dose 
n=26 
 
Female and 
male 
 
30-70yo 
 
Hepatic 
function: 
11 = Normal 
08 = Mild 
08 = Moderate 
 
 
• Febuxostat 80mg daily x 
7 days 
 
• Effect of hepatic 
impairment on the 
pharmacokinetics, 
pharmacodynamics, and 
safety of Febuxostat 
• No statistically significant 
differences in plasma 
pharmacokinetic paraments 
for febuxostat between 
subjects with mild or 
moderate hepatic 
impairment vs. with normal 
hepatic function 
 
• Serum uric acid percentage 
decrease lower in hepatic 
impaired vs. normal 
hepatic groups. 
• Author claims not 
clinically significant  
• Febuxostat 80mg 
daily appears to 
be generally safe 
and well tolerated 
in mildly and 
moderately 
impaired hepatic 
groups 
 
• No dose 
adjustment 
required in 
subjects with mild 
to moderate 
hepatic 
impairment.  
 
• Does not include 
population more 
than moderately 
impaired 
Khosravan, 
R.  
2006 Phase I 
Randomized 
Double-blind 
Placebo-
controlled 
n= 12  
 
Female and 
male 
18-55 yo 
• Febuxostat 10, 20, 30, 
40, 50, 70, 90, 120, 160, 
180, 240mg daily for 14 
days  
 
• Percentage decrease in 
serum uric acid 
concentrations ranged from 
27% to 76% for all doses 
and was dose linear for 10-
• A linear 
pharmacokinetic 
and dose-response 
relationship for 
febuxostat 
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Multicenter 
Multiple-dose 
Dose-escalation 
study 
 
10 = Feb 
02 = Placebo 
 
 
• Investigate the 
pharmacokinetics, 
pharmacodynamics and 
safety of Febuxostat over 
range of oral doses in 
healthy subjects 
120mg per day dosage 
range.  
 
• Majority of adverse events 
were mild-to-moderate in 
intensity 
 
• Febuxostat was well 
tolerated at once-daily 
doses of 10-240mg 
dosages within 
10-120mg range 
existed 
 
• Febuxostat was 
extensively 
metabolized and 
renal function did 
not seem to play 
an important role 
in elimination 
from the body 
Mayer, M. 2005 Phase I 
Parallel-group 
Open-label 
Multiple-dose 
study 
n=31 
 
Female and 
male 
 
26-76 yo 
 
Renal function: 
11 = Normal 
06 = mild  
07 = moderate 
07 = severe  
impairment  
 
• Febuxostat 80mg daily x 
7 days  
 
 
• Study the safety, 
pharmacokinetics, and 
pharmacodynamics of 
febuxostat in subjects 
with varying renal 
impairment 
• Although plasma exposure 
to febuxostat and its 
metabolites was higher in 
subjects with increasing 
degrees of renal 
impairment, the 
percentages of reduction in 
serum uric acid were 
comparable regardless of 
renal function.   
• A once-daily 
80mg dose of 
febuxostat 
appears to be safe 
and well tolerated 
in different renal 
function groups 
  
• Febuxostat does 
not appear to 
require dose 
adjustments based 
on differences in 
renal function 
Becker , 
M.A. 
2005 Phase II 
Randomized 
Multicenter 
Double-blind 
Placebo-
controlled 
Dose-response  
Clinical Trial 
n=153 
 
Female and 
male 
 
Ave age range 
=52.2yo-56.2yo  
 
37 =40mg Feb 
40 =80mg Feb 
38 =120mg Feb 
• Febuxostat 40mg, 80mg, 
120mg 
Vs. 
Placebo 
 
28-days 
 
• Assess the safety and 
efficacy of once-daily 
oral febuxostat 40mg, 
80mg, 120mg 
• Degree of serum uric acid 
reduction was significantly 
greater in all febuxostat 
treatment groups compared 
to placebo by day 7 and 
maintained over the 28-day 
study period 
 
 
• Data suggested therapeutic 
dosages likely to fall in 
• Febuxostat safe 
and effective in 
this phase II 
study.  
 
• More studies 
indicated 
necessary  
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38 =Placebo range of 80-120mg per day 
 
• Renal insufficiency not 
assessed and future studies 
indicated 
 
• Febuxostat and Placebo 
groups equal in regards to 
adverse events 
• Few serious adverse events 
occurred 
 
• Confirmation of 
mechanism achieved—
xanthine oxidase inhibition 
Becker, 
M.A. 
2004 Phase I 
Multiple-dose 
Placebo-
controlled 
Dose-escalation 
study 
n=154 
 
Female and 
male 
 
19-54 yo 
• Febuxostat 10, 20, 30, 
40, 50, 70, 90, 120, 160, 
180, 240mg daily for 14 
days  
Vs.  
Febuxostat 30mg or Placebo 
BID 
 
• Determine the safety, 
tolerability,  
pharmacokinetics, 
pharmacodynamics of 
Febuxostat over range of 
oral doses in healthy 
volunteers 
• Febuxostat effectively 
decreased serum uric acid 
concentration in a dose-
linear manner with once-
daily dosing of up to 
120mg.   
• Doses in excess of 120mg 
daily did not appear to 
provide significant 
additional hypouricemic 
effects.   
 
• Febuxostat did not appear 
to cause significant 
reduction in total purine 
synthesis 
 
• Sole mechanism of action 
of febuxostat confirmed as 
a xanthine oxidase inhibitor   
• Febuxostat is safe 
and well-tolerated 
when subjects 
were administered 
with drug in this 
study 
 
• Febuxostat 
effectively 
decreased serum 
uric acid 
concentration in a 
dose-linear 
manner with 
once-daily dosing 
of up to 120mg.   
Table 1 – Studies conducted to assess solely Febuxostat (Preapproval of FDA) 
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Author Published Study Type Sample Size Treatments Studied Outcomes Comments 
 
Schumacher  
Jr., H.R. 
MD 
2009 Cohort 
Open Label 
Non-Random 
Uncontrolled 
 
(FOCUS) 
n=116 
08 = 40mg  
79 = 80mg 
29 = 120mg 
 
-58 DC prematurely 
-38 DC first year 
-13 ADR  
 
Febuxostat 40mg, 
80mg, 120mg 
PO daily  
 
Time =5 years 
• 5 years -- 54/58 with 
sUA<6.0mg/dL 
• 5 years—18/26 complete 
resolution of tophus 
since baseline 
• No deaths  
• After 1st year of stable 
dose, subjects had <1 
gout flare per year 
 
• Long-term treatment 
with febuxostat resulted 
in durable maintenance 
of sUA <6.0 mg/dl for 
most subjects.  
• There was nearly 
complete abolition of 
gout flares in patients 
completing the study.  
• Baseline tophi resolved 
in a majority of subjects. 
• http://www.clinicaltrials.
gov/ct2/show/NCT00174
941?term=febuxostat&ra
nk=6 
Wortmann, 
R.L. 
2008 Open Label 
RCT 
Extension of 
FACT and 
APEX trials 
 
(EXCEL) 
n=1086 Febuxostat 80mg, 
120mg, 240mg 
Vs. 
Allopurinol 300mg, 
100mg (based on renal 
function) 
• Taken from subjects 
from the APEX and 
FACT studies, the 
incidence of acute gout 
flares was reduced to < 1 
per year by the 36th 
month of treatment 
amongst all drugs 
• Continuation of APEX 
and FACT studies 
• http://www.clinicaltrials.
gov/ct2/show/NCT00175
019?term=febuxostat&ra
nk=4 
 
Schumacher 
Jr., H.R. 
MD 
2008 RCT Phase 
III 
Double-blind 
167 sites US 
 
(APEX) 
 
 
n=1072 
(18-85 years of age 
with gout 
≥8.0mg/dL) 
 
Completed: 
101 = Placebo 
174 = Feb 80mg 
200 = Feb 120mg 
086 = Feb 240mg  
211 = Alo 300mg 
Febuxostat 40mg, 
80mg, 120mg, 240mg 
Vs.  
Allopurinol 300mg, 
100mg (based on renal 
function) 
Vs. 
Placebo   
 
Daily 
 
Time = 28-Week Trial  
• sUA <6.0mg/dL in last 3 
months (no renal 
impairment) 
36% = Febuxostat 80mg 
52% = Febuxostat 120mg 
66% = Febuxostat 240mg 
10% = Allopurinol  
 
(P<0.001) = Greater 
febuxostat proportion 
achieved primary end point 
• Predominantly Men 
(Ave. 93.6% Men) 
• http://www.clinicaltrials.
gov/ct2/show/NCT00174
915?term=febuxostat&ra
nk=1 
• Uncertain if health care 
administrations and staff 
were blinded to study as 
well due to absence of 
explicit explanation by 
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<6.0mg/dL vs. allopurinol or 
placebo 
 
• sUA <6.0mg/dL in last 3 
months (renal 
impairment) 
44% = Febuxostat 80mg 
46% = Febuxostat 120mg 
60% = Febuxostat 240mg 
00% = Allopurinol 100mg 
 
• sUA <6.0mg/dL at 28-
week and final visit (no 
renal impairment) 
76% = Febuxostat 80mg 
87% = Febuxostat 120mg 
94% = Febuxostat 240mg 
41% = Allopurinol 300mg 
01% = Placebo 
 
00% = Allopurinol 100mg for 
renal impairment 
 
• % reduction sUA 
-45% = Febuxostat 80mg 
-52% = Febuxostat 120mg 
-66% = Febuxostat 240mg 
-34% = Allopurinol 300mg 
-03% = Placebo 
 
• Proportion requiring 
treatment for gout flare 
(wks 8-28) 
No statistically significant 
differences between 
treatment groups 
 
author. 
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• Total # and size of tophi 
No significant differences in 
# of tophi between treatment 
groups 
 
No significant differences in 
median tophus size between 
treatment groups 
 
Mean % decrease with 
Febuxostat 120mg (-1.2) 
versus placebo (-0.3) at week 
28 (P≤0.05) 
 
• Adverse Events 
Occurred in similar 
frequency across treatment 
groups 
 
Statistically significant 
increase of diarrhea in 
febuxostat 240mg.   
 
Included: URIs, abnormal 
liver-function test results, 
diarrhea, headaches, joint-
related signs and symptoms, 
and musculoskeletal and 
connective tissue signs and 
symptoms.   
 
• Abnormal liver-function 
results— 
17/51 (6%)= 80mg Feb 
10/51 (4%)= 120mg Feb 
06/51 (4%)= 240mg Feb  
15/51 (6%)=300mg Allo 
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03/51 (2%)= Placebo 
 
• 12 withdrew due to 
abnormal LFT 
05 = Febuxostat 80mg 
03 = Febuxostat 120mg 
04 = Allopurinol 300mg 
 
• Adverse events leading 
at least to study 
discontinuation occurred 
in 78 subjects with 
similar frequency across 
treatments 
• 8 withdrew due to 
diarrhea 
 
Becker, 
M.A. MD 
2005 RCT Phase 
III 
Double-blind 
52-week 
Multicenter 
 
(FACT)  
n=762 
 
Included in efficacy 
analysis: 
255 = Feb 80mg 
250 = Feb 120mg 
251 = Alo 300mg 
Febuxostat 80mg 
Vs. 
Febuxostat 120mg 
Vs.  
Allopurinol 300mg 
 
Daily  
 
Time = 52-Week Trial 
 
• Compared the 
safety and 
efficacy of 
febuxostat with 
the safety and 
efficacy of 
allopurinol in 
adult subjects 
with gout and 
sUA ≥8.0mg/dL 
• sUA <6.0mg/dL 
53% = 80mg Febuxostat   
62% = 120mg Febuxostat  
21% = 300mg Allopurinol  
 
Reached primary endpoint of 
study by higher proportions 
of febuxostat-treated subjects 
than allopurinol-treated 
subjects.  
 
• By weeks 49-52 (final 
visit interval) flare 
incidence: 
08% = 80mg Febuxostat 
06% = 120mg Febuxostat 
11% = 300mg Allopurinol 
 
• Median % Reduction in 
tophus area amongst 156 
• Large sample size 
• http://www.clinicaltrials.
gov/ct2/show/NCT00102
440?term=febuxostat&ra
nk=2 
• Uncertain if health care 
administrations and staff 
were blinded to study as 
well due to absence of 
explicit explanation by 
author.   
 34 
subjects with tophi from 
baseline: 
83% = 80mg Febuxostat 
66% = 120mg Febuxostat 
50% = 300 mg Allopurinol 
 
No statistically significant 
differences among the groups 
in the percentage reduction in 
tophus area or in reduction in 
number of tophi 
 
• Incidence of adverse 
effects: 
Similar in the three treatment 
groups 
 
Included: abnormal liver-
function test results, diarrhea, 
headaches, joint-related signs 
and symptoms, and 
musculoskeletal and 
connective tissue signs and 
symptoms.   
 
Mild to moderate in severity. 
 
Incidence of serious adverse 
effects similar in all groups.  
Serious adverse effects 
occurred in 51 subjects, 
34/51 continued the study 
with resolution.   
 
• Most common adverse 
event leading to 
withdrawal from study: 
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o Abnormal liver-
function 
results— 
05/256 = 80mg Febuxostat 
07/251 = 120mg Febuxostat 
01/253 = 300mg Allopurinol  
(P=0.04 comparing 120mg 
Feb. vs. 200mg Allo) 
Table 2—Trials comparing Febuxostat versus Allopurinol including long-term trials of Febuxostat usage.    
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Indicated 
outcome target 
FACT Study APEX Study FOCUS Study Comments 
Uric Acid 
Level 
sUA <6.0mg/dL 
53% = 80mg Febuxostat   
62% = 120mg Febuxostat  
21% = 300mg Allopurinol  
 
Reached primary endpoint of 
study by higher proportions of 
febuxostat-treated subjects than 
allopurinol-treated subjects.  
 
(P<0.001) for comparison of each 
febuxostat group with the 
allopurinol group  
• sUA <6.0mg/dL in last 3 
months (no renal 
impairment) 
36% = Febuxostat 80mg 
52% = Febuxostat 120mg 
66% = Febuxostat 240mg 
10% = Allopurinol 300mg 
 
(P<0.001) = Greater febuxostat 
proportion achieved primary 
end point <6.0mg/dL vs. 
allopurinol or placebo 
 
• sUA <6.0mg/dL in last 3 
months (renal impairment) 
44% = Febuxostat 80mg 
46% = Febuxostat 120mg 
60% = Febuxostat 240mg 
00% = Allopurinol 100mg 
 
• sUA <6.0mg/dL at 28-
week and final visit (no 
renal impairment) 
76% = Febuxostat 80mg 
87% = Febuxostat 120mg 
94% = Febuxostat 240mg 
41% = Allopurinol 300mg 
01% = Placebo 
 
00% = Allopurinol 100mg for 
renal impairment 
 
• % reduction sUA 
-45% = Febuxostat 80mg 
-52% = Febuxostat 120mg 
• sUA<6.0mg/dL 
54/58 (93%) = Across all 
febuxostat dosages 
 
• Overall, febuxostat 
displayed a greater amount 
of uric acid reduction 
among the test subjects  
 
• Showed promising numbers 
for further study  
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-66% = Febuxostat 240mg 
-34% = Allopurinol 300mg 
-03% = Placebo 
Acute Gout 
Attacks / Flares 
By weeks 49-52 (final visit 
interval) flare incidence: 
08% = 80mg Febuxostat 
06% = 120mg Febuxostat 
11% = 300mg Allopurinol 
 
 
Proportion requiring treatment 
for gout flare (wks 8-28) 
No statistically significant 
differences between treatment 
groups 
 
After 1st year of stable dose, 
subjects had <1 gout flare per 
year 
 
• Despite febuxostat’s 
success in contrast with 
allopurinol, the resolution 
of the clinical symptoms of 
acute gout flares and tophi 
showed that febuxostat had 
no significant advantage 
over its challenger.   
Gout Tophi 
Reduction 
Median % Reduction in tophus 
area amongst 156 subjects with 
tophi from baseline: 
83% = 80mg Febuxostat 
66% = 120mg Febuxostat 
50% = 300 mg Allopurinol 
 
No statistically significant 
differences among the groups in 
the percentage reduction in tophus 
area or in reduction in number of 
tophi  
Total # and size of tophi 
No significant differences in # 
of tophi between treatment 
groups 
 
No significant differences in 
median tophus size between 
treatment groups 
 
Mean % decrease with 
Febuxostat 120mg (-1.2) versus 
placebo (-0.3) at week 28 
(P≤0.05) 
Tophi after 5 years 
 
18/26 (69%) = Complete 
resolution of tophus since 
baseline 
 
• Same as above 
Quality of life 
(as reported by 
subjects in 
study) 
Not reported by subjects Not reported by subjects Not Reported by subjects • Subjects without 
hyperuricemia do not suffer 
from its supersaturation 
effects 
• More extensive study 
necessary 
Drug Adverse 
Effects (as 
reported by 
study) 
Incidence of adverse effects: 
Similar in the three treatment 
groups 
 
Included: abnormal liver-function 
test results, diarrhea, headaches, 
joint-related signs and symptoms, 
Incidence of adverse events 
Occurred in similar frequency 
across treatment groups 
 
Included: URIs, abnormal liver-
function test results, diarrhea, 
headaches, joint-related signs 
Incidence of adverse events 
 
No deaths  
 
• Both the APEX and FACT 
studies claimed the adverse 
effects and events were 
similar across treatment 
groups including notably 
concern-causing abnormal 
liver function results.  
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and musculoskeletal and 
connective tissue signs and 
symptoms.   
 
Mild to moderate in severity. 
 
Incidence of serious adverse 
effects similar in all groups.  
Serious adverse effects occurred 
in 51 subjects, 34/51 continued 
the study with resolution.   
 
Most common adverse event 
leading to withdrawal from study: 
Abnormal liver-function results— 
05 = 80mg Febuxostat 
07 = 120mg Febuxostat 
01 = 300mg Allopurinol  
(P=0.04 comparing 120mg Feb. 
vs. 200mg Allo)  
and symptoms, and 
musculoskeletal and connective 
tissue signs and symptoms.   
 
Statistically significant increase 
of diarrhea in febuxostat 
240mg.   
 
• Abnormal liver-function 
results— 
17/51 (6%)= 80mg Feb 
10/51 (4%)= 120mg Feb 
06/51 (4%)= 240mg Feb  
15/51 (6%)=300mg Allo 
03/51 (2%)= Placebo 
 
• 12 withdrew due to 
abnormal LFT 
05 = Febuxostat 80mg 
03 = Febuxostat 120mg 
04 = Allopurinol 300mg 
 
• Adverse events leading at 
least to study 
discontinuation occurred in 
78 subjects with similar 
frequency across 
treatments 
• 8 withdrew due to diarrhea 
• Further studies that can 
concentrate on, or isolate 
the immediate and long-
term effects of febuxostat 
specifically on liver 
function need to be 
accomplished to further 
ensure safety in the 
administration of the drug.   
 
• At this point, the makers of 
febuxostat recommend 
laboratory assessment of 
liver function at 2 and 4 
months following initiation, 
and periodically thereafter 
Table 3—Comparison of outcomes from clinical trials  
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